Manufacturer of generic & innovative pharmaceuticals.
Teva's 2025 improvement is real, but most of it is being driven by the U.S., by AUSTEDO, AJOVY and UZEDY, and by revenue and cash-flow components that are not all equally recurring.
Teva's legal tail has clearly shrunk, but it still behaves like a recurring cash use: even after a 39% drop in legal settlements and loss contingencies expense to $467 million, opioid payments extend to 2030 and the broader litigation book remains open.
Teva's RCF amendment materially changes the financing read-through: it extends the backstop to April 2028, adds more headroom at the 2025 to 2026 leverage test and opens a path under which the leverage and minimum interest-cover covenants can be suspended if Teva reaches investm…
Teva generated strong liquidity in 2025, but a much smaller part of the headline free cash flow appears truly recurring once securitization and the duvakitug milestone are separated.
